Literature DB >> 28885827

Attachment Site Cysteine Thiol pKa Is a Key Driver for Site-Dependent Stability of THIOMAB Antibody-Drug Conjugates.

Breanna S Vollmar1, Binqing Wei1, Rachana Ohri1, Jianhui Zhou1, Jintang He1, Shang-Fan Yu1, Douglas Leipold1, Ely Cosino1, Sharon Yee1, Aimee Fourie-O'Donohue1, Guangmin Li1, Gail L Phillips1, Katherine R Kozak1, Amrita Kamath1, Keyang Xu1, Genee Lee1, Greg A Lazar1, Hans K Erickson1.   

Abstract

The incorporation of cysteines into antibodies by mutagenesis allows for the direct conjugation of small molecules to specific sites on the antibody via disulfide bonds. The stability of the disulfide bond linkage between the small molecule and the antibody is highly dependent on the location of the engineered cysteine in either the heavy chain (HC) or the light chain (LC) of the antibody. Here, we explore the basis for this site-dependent stability. We evaluated the in vivo efficacy and pharmacokinetics of five different cysteine mutants of trastuzumab conjugated to a pyrrolobenzodiazepine (PBD) via disulfide bonds. A significant correlation was observed between disulfide stability and efficacy for the conjugates. We hypothesized that the observed site-dependent stability of the disulfide-linked conjugates could be due to differences in the attachment site cysteine thiol pKa. We measured the cysteine thiol pKa using isothermal titration calorimetry (ITC) and found that the variants with the highest thiol pKa (LC K149C and HC A140C) were found to yield the conjugates with the greatest in vivo stability. Guided by homology modeling, we identified several mutations adjacent to LC K149C that reduced the cysteine thiol pKa and, thus, decreased the in vivo stability of the disulfide-linked PBD conjugated to LC K149C. We also present results suggesting that the high thiol pKa of LC K149C is responsible for the sustained circulation stability of LC K149C TDCs utilizing a maleimide-based linker. Taken together, our results provide evidence that the site-dependent stability of cys-engineered antibody-drug conjugates may be explained by interactions between the engineered cysteine and the local protein environment that serves to modulate the side-chain thiol pKa. The influence of cysteine thiol pKa on stability and efficacy offers a new parameter for the optimization of ADCs that utilize cysteine engineering.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28885827     DOI: 10.1021/acs.bioconjchem.7b00365

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  7 in total

Review 1.  Signed, Sealed, Delivered: Conjugate and Prodrug Strategies as Targeted Delivery Vectors for Antibiotics.

Authors:  Ana V Cheng; William M Wuest
Journal:  ACS Infect Dis       Date:  2019-04-10       Impact factor: 5.084

Review 2.  Future prospects for noncanonical amino acids in biological therapeutics.

Authors:  Arlinda Rezhdo; Mariha Islam; Manjie Huang; James A Van Deventer
Journal:  Curr Opin Biotechnol       Date:  2019-04-08       Impact factor: 9.740

3.  Click Chemistry Conjugations.

Authors:  Tak Ian Chio; Susan L Bane
Journal:  Methods Mol Biol       Date:  2020

4.  Evaluation of Cellular Targeting by Fab' vs Full-Length Antibodies in Antibody-Nanoparticle Conjugates (ANCs) Using CD4 T-cells.

Authors:  Khushboo Singh; Mine Canakci; Pintu Kanjilal; Natalie Williams; Sudarvili Shanthalingam; Barbara A Osborne; S Thayumanavan
Journal:  Bioconjug Chem       Date:  2022-02-09       Impact factor: 6.069

5.  Tumor stroma-targeted antibody-drug conjugate triggers localized anticancer drug release.

Authors:  Christopher Szot; Saurabh Saha; Xiaoyan M Zhang; Zhongyu Zhu; Mary Beth Hilton; Karen Morris; Steven Seaman; James M Dunleavey; Kuo-Sheng Hsu; Guo-Jun Yu; Holly Morris; Deborah A Swing; Diana C Haines; Yanping Wang; Jennifer Hwang; Yang Feng; Dean Welsch; Gary DeCrescenzo; Amit Chaudhary; Enrique Zudaire; Dimiter S Dimitrov; Brad St Croix
Journal:  J Clin Invest       Date:  2018-06-04       Impact factor: 14.808

Review 6.  Anti-ErbB2 immunotherapeutics: struggling to make better antibodies for cancer therapy.

Authors:  Rita De Santis
Journal:  MAbs       Date:  2020 Jan-Dec       Impact factor: 5.857

7.  Single Mutation on Trastuzumab Modulates the Stability of Antibody-Drug Conjugates Built Using Acetal-Based Linkers and Thiol-Maleimide Chemistry.

Authors:  Xhenti Ferhati; Ester Jiménez-Moreno; Emily A Hoyt; Giulia Salluce; Mar Cabeza-Cabrerizo; Claudio D Navo; Ismael Compañón; Padma Akkapeddi; Maria J Matos; Noelia Salaverri; Pablo Garrido; Alfredo Martínez; Víctor Laserna; Thomas V Murray; Gonzalo Jiménez-Osés; Peter Ravn; Gonçalo J L Bernardes; Francisco Corzana
Journal:  J Am Chem Soc       Date:  2022-03-16       Impact factor: 15.419

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.